PT-141, also called Bremelanotide (generic clinical name), is a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male/female hypoactive sexual desire disorder and acute hemorrhage. PT-141 is an agonist for the melanocortin-4 and melanocortin-1 receptors. Research shows that it promotes sexual arousal and stimulates the immune system.
Researched Benefits:
Facilitates analysis of melanocortin receptor sub-type 4 binding and signaling
Supports investigation into hypothalamic neural circuitry and sexual arousal pathways
Enables modeling of central nervous system-mediated melanocyte stimulating hormone responses
Useful for evaluating non-selective agonism in various neurochemical assay environments
Description
PT-141, also known as Bremelanotide, is a synthetic peptide analogue of the naturally occurring hormone alpha-MSH, used primarily in the study of sexual dysfunction. This peptide is derived from high-quality materials and synthesized to ensure exceptional purity and potency for comprehensive experimental use.
Key Features:
Manufactured under stringent conditions to maintain the highest purity and stability.
Undergoes rigorous testing to guarantee consistent quality across all batches.
Available in lyophilized form to preserve its properties until reconstitution.
Applications:
Research into enhancing sexual function and arousal mechanisms.
Investigations into erectile dysfunction and female sexual interest/arousal disorder.
Studying the peptide’s effects on melanocortin receptors involved in sexual arousal.
Specifications and Documentation
PT-141 is widely respected in the scientific community for its potential therapeutic applications in sexual dysfunction, offering researchers a distinct opportunity to explore this critical aspect of human health.
